Group 1 - The company West Securities Co., Ltd. announced the issuance of its corporate bonds (second phase) aimed at professional investors, with a total issuance scale of 1 billion yuan and a maturity period of 3 years [1] - The coupon rate for the bonds is set at 2.29%, with interest payments amounting to 22.90 yuan per bond (before tax) for each 1,000 yuan face value [1] - The bond's credit rating is AAA and it is unsecured, with the next interest payment date scheduled for June 4, 2025, maintaining the same interest rate [1] Group 2 - The interest payment date is June 4, 2025, with the record date for bondholders being June 3, 2025, and payments will be made through China Securities Depository and Clearing Corporation [1] - Individual and securities investment fund holders will receive a net interest of 18.32 yuan per bond after tax, while non-resident enterprises will receive the full amount of 22.90 yuan [1] - The company has committed to timely interest payments and will announce any subsequent arrangements in case of special circumstances affecting the payment process [1]

| 证券代码：002673 证券简称：西部证券 | 公告编号：2025-039 | | --- | --- | | 债券代码：149949 | 债券简称：22西部06 | | 148177 | 23西部02 | | 148339 | 23西部03 | | 148391 | 23西部04 | | 148424 | 23西部05 | | 148699 | 24西部01 | | 148753 | 24西部02 | | 148865 | 24西部03 | | 148924 | 24西部04 | | 524008 | 24西部05 | | 524106 | 25西部01 | | 524164 | 25西部02 | 西部证券股份有限公司 2024年面向专业投资者公开发行公司债券 （第二期）2025年付息公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 一、本期债券基本情况 1、发行主体：西部证券股份有限公司 2、债券名称：西部证券股份有限公司2024年面向专业投资者公 开发行公司债券（第二期） 3、债券简称：24西部02 西部证券股份有限公司 2024 年 ...

西部证券股份有限公司 关于湖南艾布鲁环保科技股份有限公司 使用部分暂时闲置募集资金及闲置自有资金进行现金管理的核查意 （证监许可2022495 号） 核准，湖南艾布鲁环保科技股份有限公司（以下简称"公司"）首次公开发行人民 币普通股（A 股）30,000,000 股，每股面值人民币 1 元,每股发行价格为 18.39 元， 募集资金总额为 551,700,000.00 元，扣除承销保荐费（不含税）41,637,735.85 元 和 其 他 相 关 发 行 费 用 （ 不 含 税 ） 18,476,483.78 元 后 ， 实 际 募 集 资 金 净 额 会计师事务所（特殊普通合伙）已于 2022 年 4 月 21 日对公司首次公开发行股票 的资金到位情况进行了审验，并出具了"CAC 证验字20220035 号" 《验资报告》。 为规范公司募集资金管理，保护投资者权益，公司与保荐人、募集资金专户 开户银行签署了《募集资金三方监管协议》，开设了募集资金专项账户，对募集 资金实行专户存储。上述全部募集资金已按规定存放于公司募集资金专户。 二、募集资金投资项目情况 见 西部证券股份有限公司（以下简称"西部证券"或"保 ...

Group 1 - The three major indices collectively retreated on May 20, with the General Aviation concept following suit, as the National General Aviation Industry Index (980076.SZ) experienced a drop of nearly 1% before recovering to a decline of 0.25% [1] - Among the index constituents, Shen Cheng Jiao and Digital Zheng Tong rose over 5%, while Hang Fa Control and Nan Wang Technology increased nearly 4% [1] - The General Aviation ETF (159230) fell nearly 1%, with a trading volume of 134 million yuan, making it the top performer in its category, and its latest circulation size is 267 million yuan [1] Group 2 - The General Aviation ETF closely tracks the National General Aviation Industry Index, focusing on the general aviation and low-altitude economy industry chain, with low-altitude economic content at 84.7%, defense and military content at 58.6%, and domestic large aircraft content at 47.4% [2] - Western Securities emphasizes the importance of monitoring domestic low and high orbit constellation progress, alongside breakthroughs in rocket technology and military communication as indirect catalysts [2] - The focus on low orbit includes the initial network completion of StarNet and Qianfan constellations, while high orbit attention is on the commercialized constellations of Tiantong and Beidou, with potential catalysts from new products or value-added services [2]

证券代码：【 524283 】 证券简称：【 25 西部 K1 】 西部证券股份有限公司 2025 年面向专业投资者公开发行科技创 特此公告。 （本页以下无正文） 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整， 并对 公告中的虚假记载、误导性陈述或者重大遗漏承担责任。 西部证券股份有限公司（以下简称"发行人"）发行不超过人民币 180 亿元 公司债券已获得中国证券监督管理委员会证监许可﹝2024﹞60 号文注册。西部 证券股份有限公司 2025 年面向专业投资者公开发行科技创新公司债券（第一期） （以下 简称"本期债券"）发行规模为不超过（含）10 亿元。 2025 年 5 月 29 日，发行人和主承销商在网下向专业机构投资者进行了票面 利率询价，利率询价区间为 1.5%-2.5%。根据网下向专业机构投资者询价结果， 经发行人和主承销商协商一致，最终确定本次债券票面利率为【1.92】% 。 发行人将按上述票面利率于 2025 年 5 月 30 日面向专业机构投资者网下发 行。具体认购方法请参考 2025 年 5 月 27 日刊登在深圳证券交易所网站 （http://www.szse.cn）、 ...

(本页无正文,为《关于延长西部证券股份有限公司 2025 年面向专业投资者公 开发行科技创新公司债券(第一期)簿记建档时间的公告》之盖章页) 发行人:西部记 2025 (本页无正文,为《关于延长西部证券股份有限公司 2025年面向专业投资者公 开发行科技创新公司债券(第一期)簿记建档时间的公告》之盖章页） 关于延长西部证券股份有限公司 2025 年面向专业投资者公开发行科技创 新公司债券（第一期）簿记建档时间的公告 西部证券股份有限公司（以下简称"发行人"）面向专业投资者公开发行总额 不超过 180 亿元公司债券（以下简称"本次债券"）已获得中国证券监督管理委员 会《关于同意西部证券股份有限公司面向专业投资者公开发行公司债券注册的批 复》（证监许可﹝2024﹞60 号）。西部证券股份有限公司 2025 年面向专业投资 者公开发行科技创新公司债券（第一期）（以下简称"本期债券"）发行规模不 超过 10 亿元（含 10 亿元）。 根据《西部证券股份有限公司 2025 年面向专业投资者公开发行科技创新公 司债券（第一期）发行公告》，发行人和主承销商将于【2025】年【5】月【29】 日【15】：00 至【18】：0 ...

Core Viewpoint - Anke Biotech aims for restorative growth in 2025, focusing on enhancing sales of water injections and promoting the recovery of growth hormone sales while optimizing its traditional Chinese medicine segment and expanding its peptide and chemical drug markets [2][4][5]. Business Strategy - The company plans to strengthen academic promotion and increase the sales proportion of water injections, while also pushing for the recovery of growth hormone sales [2]. - The traditional Chinese medicine segment has resumed production since December 2024, with efforts to optimize sales policies and maintain growth in traditional Chinese medicine [2]. - The peptide segment will focus on market analysis and expanding the sales scale of raw materials for enterprises that win centralized procurement bids [2]. - The company intends to divest its forensic-related business and actively transition to new business areas [2]. Investment Activities - Anke Biotech has made cornerstone investments in Weisheng Pharmaceutical, aiming to establish a long-term cooperative relationship and enhance strategic collaboration to improve risk resistance and core competitiveness [3]. Sales Performance - In Q1 2025, the company reported a year-on-year increase in new patients for growth hormone, reversing a previous decline, with shipping showing an upward trend [4]. - The product Trastuzumab is in a rapid market introduction phase, with sales exceeding 100 million yuan in 2024 and expected significant year-on-year growth in 2025 [5]. Research and Development - The company is advancing several clinical trials, including Hu1 injection for HER2 targets, which has shown promising safety and efficacy in early studies [6]. - The recombinant anti-VEGF humanized monoclonal antibody has completed phase III clinical trials, and the company is working on its market application [6]. - The company is also developing innovative drugs targeting HER2 and has submitted IND applications for several projects [6]. Financial Overview - In Q1 2025, Anke Biotech reported a main revenue of 629 million yuan, a year-on-year decrease of 4.17%, and a net profit of 209 million yuan, also down 4.02% [8]. - The company has a debt ratio of 16.52% and a gross profit margin of 76.96% [8]. - Recent institutional ratings indicate a buy recommendation from two firms, with a target average price of 10.08 yuan [8].

Core Viewpoint - Major brokerages are optimistic about the A-share market in the second half of 2025, anticipating a structural bull market driven by multiple policy benefits and industrial upgrades [1][2]. Market Outlook - Brokerages such as Industrial Securities, CITIC Securities, and Everbright Securities predict a "structural bull" market for the capital market in the second half of 2025 [2]. - Industrial Securities' chief strategist Zhang Yidong believes that A-shares will exhibit characteristics of "stable index, structural bull" in the long term, highlighting the attractive valuation of Chinese assets [2]. - CITIC Securities' chief A-share strategist Qiu Xiang expects a bull market for equity assets starting from Q4 2025, with a significant shift in market style towards core assets [2]. - Everbright Securities' chief strategist Zhang Yusheng notes that the gradual recovery of fundamentals, along with macro and micro liquidity, will drive market growth, leading to a structural bull market [2][3]. Sector Preferences - Investment opportunities in the second half of the year should focus on four key areas according to Industrial Securities' chief strategist Zhang Qiyao: technology trends marked by DeepSeek, domestic service consumption, dividend assets, and sectors like gold and military [4]. - Qiu Xiang emphasizes the importance of increasing allocations to Hong Kong stocks and focusing on leading companies in emerging and traditional industries [4]. - Open Source Securities' chief strategist Wei Jixing suggests five focus areas: domestic consumption, technology growth in AI and robotics, industries with improved costs, sectors benefiting from overseas opportunities, and stable dividend stocks [4]. - Li Chao from Zheshang Securities advocates for a focus on dividend-related sectors and technology, anticipating adjustments in institutional allocation due to new public fund regulations [4].

Group 1 - The securities industry is entering a new development stage, with firms adjusting their strategic layouts and showing a clear investor-oriented approach during performance briefings [2][3] - Nearly 20 securities firms, including Shenwan Hongyuan, Northeast Securities, Western Securities, and Changjiang Securities, have engaged deeply with investors through various channels [1][3] Group 2 - Cash dividends have become a key focus in communications between securities firms and investors, with Shanxi Securities committing to a cash dividend policy since its listing, planning to increase the cash dividend ratio from at least 10% to at least 30% of distributable profits for 2024 to 2026 [4] - Changjiang Securities has maintained a stable dividend philosophy, having implemented cash dividends for 17 consecutive years, ranking high among listed securities firms [4] Group 3 - The ongoing merger and acquisition (M&A) trend in the securities industry is a focal point for investors, with Western Securities currently undergoing regulatory review for its acquisition of Guorong Securities [5] - Guosheng Jinkong is actively communicating with relevant departments regarding the complex absorption and merger with Guosheng Securities, while Zhejiang Securities and Guodu Securities are also progressing with their integration plans [5] - The acceleration of industry consolidation through multiple ongoing M&A cases is expected to optimize the industry structure and enhance market concentration, ultimately creating greater value for investors [5]

Group 1: Monetary Policy and Market Operations - The central bank conducted a 7-day reverse repurchase operation of 215.5 billion yuan at a fixed rate of 1.40% on May 28, resulting in a net injection of 58.5 billion yuan after accounting for 157 billion yuan in reverse repos maturing on the same day [2][4] - Liquidity remains ample, with overnight and 7-day pledged repo rates declining by over 3 basis points and 1 basis point, respectively [4] - The latest overnight financing rate in the U.S. stands at 4.26% [4] Group 2: Interbank Rates and Bond Yields - The latest transaction for one-year interbank certificates of deposit is around 1.72%, showing a slight increase from the previous day [7] - The yields on major interbank bonds are as follows: 1-year government bonds at 1.4625%, 2-year at 1.4725%, and 10-year at 1.6830% [8] - The 30-year main contract for government bond futures fell by 0.04%, while the 10-year contract remained unchanged [11] Group 3: Corporate and Government Financial Data - From January to April, state-owned and state-controlled enterprises reported total operating revenue of 26.2755 trillion yuan, unchanged from the previous year, while total profit decreased by 1.7% to 1.34914 trillion yuan [12] - The asset-liability ratio for these enterprises increased by 0.2 percentage points to 65.1% [12] Group 4: International Relations and Economic Policies - The Chinese government announced an expansion of visa-free access for citizens of Saudi Arabia, Oman, Kuwait, and Bahrain, effective from June 9, 2025, to June 8, 2026, facilitating business and tourism [12] - The European Union aims to reduce carbon emissions by 54% by 2030, slightly below its 55% target, while also striving for at least 42.5% of renewable energy [14] Group 5: Bond Issuance and Market Events - The Ministry of Finance plans to issue 68 billion yuan in government bonds in Hong Kong this year [17] - Recent negative events in the bond market include downgrades in ratings for several companies, such as Wuzhou Canghai Construction Development Co. and Jineng Technology Co., indicating potential risks in the corporate bond sector [17]